Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Toripalimab Becomes First Approved Immunotherapy for Recurrent Unresectable/Metastatic NPC in Canada

October 24th 2025

Toripalimab has been approved by Health Canada both as monotherapy and in combination with cisplatin and gemcitabine for recurrent or metastatic NPC.

FDA Grants Breakthrough Therapy Designation to Zenocutuzumab in NRG1+ Cholangiocarcinoma

October 24th 2025

Zenocutuzumab has received BTD from the FDA for patients with advanced unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion.

Cadonilimab Plus Chemo Retains Clinically Meaningful Survival Advantage in Frontline Gastric/GEJ Adenocarcinoma

October 23rd 2025

First-line cadonilimab plus chemotherapy demonstrated long-term efficacy benefits vs chemotherapy alone in patients with advanced gastric or GEJ adenocarcinoma.

Frontline EIK1001 Plus Chemoimmunotherapy Stimulates Antitumor Activity in Advanced NSCLC

October 20th 2025

EIK1001 plus pembrolizumab and chemo showed a 64% ORR and manageable safety in first-line stage IV NSCLC, per phase 2 TeLuRide-005 data.

NADINA Trial Favors Neoadjuvant Nivolumab/Ipilimumab in Resectable Stage III Melanoma

October 20th 2025

Neoadjuvant nivolumab plus ipilimumab proved superior to adjuvant nivolumab alone with longer follow-up data from the NADINA trial in stage III melanoma.

Tislelizumab Plus Chemo/Concurrent Chemoradiotherapy Yields Survival Advantage in Locally Advanced ESCC

October 19th 2025

Tislelizumab plus induction chemotherapy and concurrent chemoradiation demonstrated efficacy worthy of further study in locally advanced ESCC.

Zipalertinib Shows Early Efficacy With Manageable Safety in EGFR-Mutant NSCLC With CNS or Leptomeningeal Disease

October 19th 2025

Zipalertinib demonstrated preliminary efficacy and low rates of treatment-related dose reductions and discontinuations in NSCLC harboring EGFR mutations and CNS metastases and/or leptomeningeal disease.

Invikafusp Alfa Boasts High Disease Control Rate in Checkpoint Inhibitor–Resistant Solid Tumors

October 18th 2025

Invikafusp alfa demonstrated early signals of antitumor activity across a range of biomarker-enriched patients with solid tumors.

Phase 2 BNT111/Cemiplimab Data Prove Positive in PD-(L)1-Relapsed/Refractory Melanoma

October 18th 2025

BNT111 plus cemiplimab achieved an 18.1% ORR in PD-(L)1–refractory melanoma, meeting its primary end point in the phase 2 BNT111-01 trial.

Dr Sridhar on the Importance of Patient Selection for Benefit With Avelumab in PSCC

October 18th 2025

Srikala Sridhar, MD, MSc, FRCPC, discusses efficacy findings from the ALPACA study and the necessity of improved patient selection for checkpoint inhibitors in PSCC

Dato-DXd Plus Rilvegostomig Elicits Activity in Cisplatin-Ineligible or Platinum-Pretreated Urothelial Cancer

October 18th 2025

Datopotamab deruxtecan plus rilvegostomig was active in cisplatin-ineligible and platinum-pretreated locally advanced or metastatic urothelial cancer.

Lenvatinib Plus Pembrolizumab and Chemotherapy Fails to Improve OS in Advanced ESCC

October 17th 2025

First-line treatment with lenvatinib, pembrolizumab, and chemotherapy did not improve OS vs chemoimmunotherapy in patients with advanced ESCC.

Dr Necchi on Biomarker Data From the SunRISe-4 Trial of Gemcitabine Intravesical System Plus Cetrelimab in MIBC

October 17th 2025

Andrea Necchi, MD, discusses the role of minimal residual disease assessment in the phase 2 SunRISe-4 trial evaluating TAR-200 plus cetrelimab in MIBC.

Dr Mok on Final OS Data From the ALEX Study Evaluating First-Line Alectinib in ALK+ NSCLC

October 17th 2025

Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO, shares final OS data from the phase 3 ALEX study in ALK-positive NSCLC.

Dr O’Shaughnessy on Highly Anticipated Breast Cancer Data to Watch at ESMO 2025

October 16th 2025

Joyce A. O’Shaughnessy, MD, highlights the breast cancer data being presented at ESMO 2025 that have the greatest potential to shape clinical practice.

JAK Inhibitors Persist, While Novel Agents Aim for Disease Modification in Myelofibrosis

October 16th 2025

Aaron Gerds, MD, MS, discusses the clinical applications of each of the FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

Izalontamab Brengitecan Data Reinforce the Value of ADCs in Advanced Urothelial Carcinoma

October 15th 2025

Izalontamab brengitecan showed signals of activity in patients with pretreated locally advanced or metastatic urothelial carcinoma.

Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer

October 15th 2025

Maintenance rucaparib showed efficacy in recurrent/metastatic endometrial cancer after the completion of first- or second-line chemotherapy.

64Cu-SAR-bisPSMA Bests SOC 68Ga-PSMA-11 PET/CT in Detecting PSMA-Positive Prostate Cancer Lesions

October 14th 2025

64Cu-SAR-bisPSMA displayed a higher detection rate of PSMA-positive prostate cancer lesions vs 68Ga-PSMA-11 PET/CT in patients with low PSA levels.

Tucatinib Plus Trastuzumab and Pertuzumab Maintenance Improves PFS in HER2+ Metastatic Breast Cancer

October 14th 2025

Combining tucatinib with trastuzumab and pertuzumab improved PFS as first-line maintenance in patients with HER2-positive metastatic breast cancer.